a Randomized Double-blind Study, PHYTOTHERAPIE, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Conditions
Brief summary
Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination. Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America. At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.
Detailed description
Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies. History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name vitamin P because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.
Interventions
DRUGQuercetin
Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
Sponsors
Hôpital Universitaire Sahloul
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* all patients attending the emergency department for influenza-like illness. * Being over 18 years old
Exclusion criteria
* Any patient requiring admission * Non-consenting patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients | 10 DAYS | Number of patients attending the emergency room |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disappearance of symptoms | 10 days | Date of disappearance of symptoms present on admission |
| adverse reaction | 10 days | Presence of an adverse reaction due to the administration of the treatment |
Countries
Tunisia
Outcome results
None listed